Personalized Treatment to Combat Antibiotic-Resistant Bacteria: Commercialization Target Set for 2030 [Interview]
AI 요약 정보
- Hallym and Uppsala develop CombiANT for tailored therapy
- CombiANT aims to identify effective combinations in 24 hours
- Team targets clinical validation and commercialization by 2030
